NO20076121L - Behandlinger for kardiovaskulaer sykdom - Google Patents
Behandlinger for kardiovaskulaer sykdomInfo
- Publication number
- NO20076121L NO20076121L NO20076121A NO20076121A NO20076121L NO 20076121 L NO20076121 L NO 20076121L NO 20076121 A NO20076121 A NO 20076121A NO 20076121 A NO20076121 A NO 20076121A NO 20076121 L NO20076121 L NO 20076121L
- Authority
- NO
- Norway
- Prior art keywords
- treatments
- cardiovascular disease
- agents
- methods
- cardiac dysfunction
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 230000000747 cardiac effect Effects 0.000 abstract 2
- 230000004064 dysfunction Effects 0.000 abstract 2
- 230000004217 heart function Effects 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000004218 vascular function Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Den foreliggende oppfinnelsen gjelder fremgangsmåter og midler for behandling av svekket karfunksjon og hjertefunksjon. Fremgangsmåter og midler for behandling av forskjellige fysiologiske og patologiske tilstander forbundet med kardysfunksjon og hjertedysfunksjon tilveiebringes også.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67849505P | 2005-05-05 | 2005-05-05 | |
US69095705P | 2005-06-15 | 2005-06-15 | |
US73443305P | 2005-11-07 | 2005-11-07 | |
PCT/US2006/017760 WO2006122047A1 (en) | 2005-05-05 | 2006-05-05 | Cardiovascular disease therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20076121L true NO20076121L (no) | 2008-02-04 |
Family
ID=36778299
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20076121A NO20076121L (no) | 2005-05-05 | 2007-11-27 | Behandlinger for kardiovaskulaer sykdom |
NO20076241A NO20076241L (no) | 2005-05-05 | 2007-12-04 | Terapier for vaskulaere sykdommer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20076241A NO20076241L (no) | 2005-05-05 | 2007-12-04 | Terapier for vaskulaere sykdommer |
Country Status (10)
Country | Link |
---|---|
US (3) | US20060281668A1 (no) |
EP (2) | EP1891109A1 (no) |
JP (2) | JP2008540456A (no) |
AU (2) | AU2006244148A1 (no) |
CA (2) | CA2607044A1 (no) |
IL (2) | IL187115A0 (no) |
MX (2) | MX2007013834A (no) |
NO (2) | NO20076121L (no) |
NZ (1) | NZ563493A (no) |
WO (2) | WO2006122047A1 (no) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007098065A2 (en) * | 2006-02-17 | 2007-08-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Human sodium channel isoforms |
US20080075666A1 (en) * | 2006-08-25 | 2008-03-27 | Dudley Samuel C Jr | Methods and compositions for treating diastolic dysfunction |
US9114133B2 (en) | 2006-08-25 | 2015-08-25 | U.S. Dept. Of Veterans Affairs | Method of improving diastolic dysfunction |
US9220720B2 (en) | 2007-10-18 | 2015-12-29 | U.S. Department Of Veterans Affairs | Method for ameliorating or preventing arrhythmic risk associated with cardiomyopathy |
US9050350B2 (en) | 2007-10-18 | 2015-06-09 | U.S. Department Of Veterans Affairs | Method for modulating or controlling connexin 43(Cx43) level of a cell and reducing arrhythmic risk |
US9114151B2 (en) * | 2007-10-18 | 2015-08-25 | The United States Of America Dept. Of Veterans Affairs | Method for modulating or controlling sodium channel current by reactive oxygen species (ROS) originating from mitochondria |
US9211301B2 (en) | 2007-10-18 | 2015-12-15 | U.S. Department Of Veterans Affairs | Method for ameliorating or preventing arrhythmic risk associated with cardiomyopathy by improving conduction velocity |
DK2331141T3 (en) | 2008-08-25 | 2016-04-04 | Excaliard Pharmaceuticals Inc | Antisense oligonucleotides WHO IS TARGETING connective tissue, AND USES THEREOF |
US8946172B2 (en) | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
WO2010032007A1 (en) * | 2008-09-18 | 2010-03-25 | Universitetet I Oslo | Use of ctgf as a cardioprotectant |
US20110262398A1 (en) * | 2010-04-21 | 2011-10-27 | University Of Illinois | Cardiac treatment using anti-fibrotic agents |
KR101249041B1 (ko) | 2010-04-28 | 2013-03-29 | 포항공과대학교 산학협력단 | 결합조직 성장인자를 이용한 약학적 조성물 |
TWI593416B (zh) | 2011-02-02 | 2017-08-01 | 艾克厘德製藥公司 | 利用針對結締組織生長因子(ctgf)目標之反義化合物治療瘢痕或肥厚性疤痕之方法 |
DE102012103096A1 (de) * | 2012-04-11 | 2013-10-17 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Prophylaxe und Behandlung einer Gefäßkalzifizierung |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5770209A (en) | 1991-08-30 | 1998-06-23 | University Of South Florida | Acceleration of wound healing using connective tissue growth factor |
US7384634B2 (en) * | 1991-08-30 | 2008-06-10 | University Of South Florida | Connective tissue growth factor |
US5408040A (en) | 1991-08-30 | 1995-04-18 | University Of South Florida | Connective tissue growth factor(CTGF) |
JPH11180895A (ja) | 1997-09-12 | 1999-07-06 | Masaharu Takigawa | 血管新生阻害剤 |
AU1682699A (en) * | 1997-12-25 | 1999-07-19 | Japan Tobacco Inc. | Monoclonal antibody against connective tissue growth factor and medicinal uses thereof |
WO2000002450A1 (en) | 1998-07-08 | 2000-01-20 | Fibrogen, Inc. | Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives |
AU775391B2 (en) | 1998-12-14 | 2004-07-29 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
US7115390B1 (en) * | 1998-12-14 | 2006-10-03 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
CA2400628A1 (en) * | 2000-03-09 | 2001-09-13 | Genzyme Corporation | Use of tgf-beta antagonists to treat or to prevent loss of renal function |
US6965025B2 (en) * | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
EP1463531B1 (en) | 2001-12-11 | 2011-09-28 | Fibrogen, Inc. | Methods for inhibiting ocular processes |
US7405274B2 (en) * | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
US20050214294A1 (en) | 2004-02-11 | 2005-09-29 | Allan Flyvbjerg | Diabetic nephropathy therapies |
-
2006
- 2006-05-05 US US11/418,787 patent/US20060281668A1/en not_active Abandoned
- 2006-05-05 CA CA002607044A patent/CA2607044A1/en not_active Abandoned
- 2006-05-05 NZ NZ563493A patent/NZ563493A/en not_active IP Right Cessation
- 2006-05-05 JP JP2008510315A patent/JP2008540456A/ja active Pending
- 2006-05-05 EP EP06752410A patent/EP1891109A1/en not_active Withdrawn
- 2006-05-05 JP JP2008510316A patent/JP5068253B2/ja active Active
- 2006-05-05 CA CA002606778A patent/CA2606778A1/en not_active Abandoned
- 2006-05-05 AU AU2006244148A patent/AU2006244148A1/en not_active Abandoned
- 2006-05-05 MX MX2007013834A patent/MX2007013834A/es not_active Application Discontinuation
- 2006-05-05 WO PCT/US2006/017760 patent/WO2006122047A1/en active Application Filing
- 2006-05-05 WO PCT/US2006/017759 patent/WO2006122046A2/en active Application Filing
- 2006-05-05 US US11/418,624 patent/US8088381B2/en active Active
- 2006-05-05 AU AU2006244147A patent/AU2006244147A1/en not_active Abandoned
- 2006-05-05 EP EP06759334A patent/EP1885756A2/en not_active Withdrawn
- 2006-05-05 MX MX2007013819A patent/MX2007013819A/es not_active Application Discontinuation
-
2007
- 2007-11-01 IL IL187115A patent/IL187115A0/en unknown
- 2007-11-01 IL IL187113A patent/IL187113A/en not_active IP Right Cessation
- 2007-11-27 NO NO20076121A patent/NO20076121L/no not_active Application Discontinuation
- 2007-12-04 NO NO20076241A patent/NO20076241L/no not_active Application Discontinuation
-
2011
- 2011-10-21 US US13/279,086 patent/US20120039882A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2008540456A (ja) | 2008-11-20 |
US20120039882A1 (en) | 2012-02-16 |
JP2008540457A (ja) | 2008-11-20 |
IL187113A (en) | 2011-06-30 |
NO20076241L (no) | 2008-02-04 |
US20060281667A1 (en) | 2006-12-14 |
CA2607044A1 (en) | 2006-11-16 |
WO2006122046A2 (en) | 2006-11-16 |
WO2006122047A1 (en) | 2006-11-16 |
JP5068253B2 (ja) | 2012-11-07 |
MX2007013834A (es) | 2008-02-05 |
US8088381B2 (en) | 2012-01-03 |
IL187113A0 (en) | 2008-02-09 |
NZ563493A (en) | 2010-10-29 |
EP1891109A1 (en) | 2008-02-27 |
IL187115A0 (en) | 2008-02-09 |
US20060281668A1 (en) | 2006-12-14 |
AU2006244148A1 (en) | 2006-11-16 |
MX2007013819A (es) | 2008-02-05 |
CA2606778A1 (en) | 2006-11-16 |
EP1885756A2 (en) | 2008-02-13 |
AU2006244147A1 (en) | 2006-11-16 |
WO2006122046A3 (en) | 2007-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20076121L (no) | Behandlinger for kardiovaskulaer sykdom | |
ATE355852T1 (de) | Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten | |
RS20150135A1 (en) | TREATMENT WITH ANTI-VEGF ANTIBODIES | |
ATE446102T1 (de) | Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii | |
EA201001695A1 (ru) | Применение эпотилона d для лечения заболеваний, связанных с тау-белком | |
DE602006007093D1 (de) | Kombinationstherapie zur Behandlung von Diabetes und dadurch bedingten Leiden sowie zur Behandlung von mittels Erhöhung des GLP-1-Spiegels im Blut verbesserten Leiden | |
EP1532269A4 (en) | 1L1RL-1 AS A MARKER OF CARDIOVASCULAR DISEASES AND THERAPEUTIC TARGET | |
SG149027A1 (en) | Substituted urea derivatives for treating cardiac diseases | |
MA28935B1 (fr) | Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite | |
EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
DK1487431T3 (da) | Forebyggelse og/eller behandling af cardiovaskulær sygdom og/eller dermed associeret hjertefejl | |
ATE473735T1 (de) | Beta-2 adrenoceptor agonisten zur behandlung von bindegewebserkrankungen der haut | |
WO2009149486A3 (en) | Compounds for treating beta-amyloidoses | |
EA200701995A1 (ru) | Способы уменьшения кальцификации | |
DE602005008013D1 (de) | Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie | |
ATE460940T1 (de) | Eisen(iii) komplex-verbindungen zur oralen behandlung von eisenmangel bei patienten mit chronischen entzündlichen darmerkrankungen | |
EA200801310A1 (ru) | Фармацевтические препараты и их применение при лечении половой дисфункции у женщин | |
DE602004023721D1 (de) | Zusammensetzungen und methoden für die behandlung von herzerkrankungen | |
NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
NO20070996L (no) | Fremgangsmate for behandling av CCR2 medierte sykdommer eller lidelser | |
ATE395919T1 (de) | Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen | |
WO2006109170A3 (en) | Combination therapy for treatment of cardiovascular diseases and related conditions | |
DK1596879T3 (da) | Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis | |
NO20033541L (no) | Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer | |
WO2006091729A3 (en) | Revascularization of ischemic retinal tissue and screening method therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |